Biotechnology

Microsoft and Bristol Myers Squibb Partner to Enhance Lung Cancer Detection

Microsoft partners with Bristol Myers Squibb to use AI for early lung cancer detection, targeting underserved areas for better healthcare access.

NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Transform Drug Discovery

NVIDIA and Lilly are launching an AI lab to redefine drug discovery, with a commitment of up to $1B over five years.

3D Systems Secures FDA Clearance Amid Financial Pressures

Abivax (ABVX): Q3 2025 Financial Results and Trial Updates

Enlivex Therapeutics Initiates Innovative Digital Asset Treasury Strategy

Enlivex Therapeutics invests $212 million into a RAIN-based digital asset treasury, doubling the token’s value and marking a pioneering move.

ARK Invest Adjusts Portfolio by Selling Palantir Shares for Crypto and Biotech Investments

ARK Invest sold over 38,000 Palantir shares, reallocating funds to crypto and biotech, reflecting a strategy to balance its investment portfolio.

Latest IPOs and Secondary Offerings You Should Know

Several companies are entering the IPO and secondary offering market, reflecting investor interest and growth funding opportunities.

YZi Labs Launches $1 Billion Builder Fund to Ignite Innovation in the BNB Ecosystem

YZi Labs has launched a $1 billion Builder Fund to support innovation in the BNB ecosystem focusing on Web3, AI, and biotech projects.

Telomir Pharma Stock Soars 35% on Epigenetic Therapy Breakthrough

Telomir Pharmaceuticals surged after new data showed its lead drug could reset disease drivers, sparking investor buzz in a high-risk biotech play.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

ProKidney Stock (PROK): Is the Hype Justified?

ProKidney's stock soared after promising Phase 2 trial results, highlighting the potential but also the risks in biotech investments.

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development

Recursion Pharmaceuticals partners with MIT for Boltz-2, an AI model predicting binding affinity at unprecedented speed and accuracy.

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus

Taysha Gene Therapies (NASDAQ: TSHA) is gaining investor attention with TSHA-102, its lead Rett syndrome gene therapy. Learn why this biotech stock is a rising contender in the CNS space.

Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals

Cidara Therapeutics aims to innovate antivirals with CD388, targeting flu prevention. Positive trial results may boost stock.

Vigil Neuroscience Stock (VIGL): Buyout Boosts Valuation

Vigil Neuroscience's stock soared after Sanofi agreed to buy it for $8.00 per share, tied to the potential success of its Alzheimer’s drug VG-3927.